Tocco Report: BIOECONOMY 2025 EDITION
State of Biomaterials and Biomanufacturing
In 2025, the lines between the lab and the factory floor are blurring: microbes are brewing fuels and fabrics, and designers are collaborating with molecular biologists. The global biomaterials market surged to $178 billion in 2023 and is projected to exceed $761 billion by 2033 (15.6% CAGR), signaling that bio-based materials are moving from fringe concept to mainstream commodity. Investor confidence is returning as well – biomaterials companies raised $392 million in funding in Q1 2025 alone, after a few rocky years.
This Tocco Report provides an in-depth, comprehensive overview of the biomaterials and biomanufacturing landscape in 2025, with a global and cross-sectoral perspective.

Explore This Report
Start with the Free Version or unlock the Full Report with deeper insights, case studies, and extra content.
- Bioeconomy on the Rise – Geopolitics and Strategy:
How nations are positioning themselves in the biotech race,
and why 2025 is a pivotal year for bio-industrial strategy. - Designing with Nature’s Building Blocks:
Innovations in packaging, textiles, and construction materials
that leverage biology for sustainable design. - Biomanufacturing for Food and Agriculture:
How fermentation and cellular agriculture are transforming
protein production and farm supply chains. - Bioindustrial Platforms – Chemicals, Energy, and Critical Minerals:
The deployment of microbes and bio-processes in heavy industry
– from making fuels and plastics to extracting critical minerals. - Scaling the Bio-Revolution – Investment, Policy, and Future Outlook:
What it will take to realize the potential of biomaterials, including investment trends, policy frameworks, workforce development, and a look ahead to 2030. - Glossary

Materials in focus
Explore the innovative materials shaping the future

Biodegradable

Recycled

Bamboo

Mycelium

Silk
What's inside?
Ginkgo Bioworks: A Boston-based “biofoundry” company that programs cells for pharma, materials, and more. Ginkgo’s high-throughput labs (with robot automation) can design and scale organisms for clients – over 100 organism programs to date. It went public in 2021 at a $15 billion valuation, has major deals (e.g. with Bayer for nitrogen-fixing microbes), and U.S. government contracts (biosecurity). Flagship for U.S. bioeconomy, Ginkgo is building capacity so “making what we invent” stays onshore.
somethingOther Available Reports
Expand your knowledge with our curated collection of industry-leading insights
Latest Design Stories
Weekly highlights from our community of innovators and pioneers